Company Profile

Sigilon Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company's Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company's lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). It is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. It also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-08-14	Eli Lilly Completes Purchase of Sigilon Therapeutics in Cash Deal	MT
23-08-14	Eli Lilly Completes Acquisition of Sigilon Therapeutics	MT
23-08-11	Sigilon Therapeutics, Inc. Announces Board Changes	CI
23-08-11	Sigilon Therapeutics, Inc.(NasdaqGM:SGTX) dropped from NASDAQ Composite Index	CI
23-08-11	Sigilon Therapeutics, Inc.(NasdaqGS:SGTX) dropped from S&P TMI Index	CI
23-08-10	Eli Lilly and Company completed the acquisition of remaining 91.56% stake in Sigilon Therapeutics, Inc. from Flagship Ventures Fund V, L.P. and Flagship Pioneering Special Opportunities Fund II, L.P., managed by Flagship Pioneering and others.	CI
23-08-07	Sigilon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-05	Canaccord Genuity Adjusts Price Target on Sigilon Therapeutics to $30 From $6, Maintains Buy Rating	MT
23-06-30	Morgan Stanley Adjusts Price Target on Sigilon Therapeutics to $21 From $7, Maintains Equalweight Rating	MT
23-06-30	BTIG Downgrades Sigilon Therapeutics to Neutral From Buy	MT
23-06-29	Sector Update: Health Care Stocks Advancing Late Thursday	MT
23-06-29	Top Midday Gainers	MT
23-06-29	Top Stories at Midday: US Q1 GDP Revised Higher; Jobless Claims Post Surprise Drop; Powell Reiterates Comments; BioXcel Therapeutics Tumbles	MT

23-07-05	Canaccord Genuity Adjusts Price Target on Sigilon Therapeutics to $30 From $6, Maintains Buy Rating	MT
23-06-30	Morgan Stanley Adjusts Price Target on Sigilon Therapeutics to $21 From $7, Maintains Equalweight Rating	MT
23-06-30	BTIG Downgrades Sigilon Therapeutics to Neutral From Buy	MT
23-01-18	Canaccord Genuity Initiates Coverage on Sigilon Therapeutics With Buy Rating, $6 Price Target	MT
22-02-01	Morgan Stanley Adjusts Sigilon Therapeutics Price Target to $2 From $4.50, Maintains Equalweight Rating	MT

23-08-14	Lilly completes biopharma acquisitions	AQ
23-08-14	Lilly Completes Acquisition of Sigilon Therapeutics	PR
23-08-11	Sigilon Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
23-07-21	SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX	BU
23-07-03	SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX	BU

23-08-14	Eli Lilly : les rachats de Versanis et Sigilon sont bouclés
23-06-29	Aktien New York Schluss: Banken geben Dow Schwung - Nasdaq schwächelt
23-06-29	Eli Lilly and : attendu en hausse après l'annonce du rachat de Sigilon Therapeutics
23-06-29	Eli Lilly : accord pour l'acquisition de Sigilon Therapeutics

Manager	Title	Age	Since
Josias Fantato De Pontes DFI	Director of Finance/CFO	60	2022-02-17
Jonathan Haug PSD	President	-	-
Bernd Kullmann COO	Chief Operating Officer	-	-

Sigilon Therapeutics, Inc. Stock

Stocks

SGTX

US82657L2060

Biotechnology & Medical Research

Latest news: Sigilon Therapeutics, Inc.

Analysts' recommendations: Sigilon Therapeutics, Inc.

Press Releases: Sigilon Therapeutics, Inc.

News in other languages: Sigilon Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Sigilon Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
Gordon Brooks BRD	Director/Board Member	-	2023-08-10
Michael Thompson BRD	Director/Board Member	-	2023-08-10
Stephen Oesterle BRD	Director/Board Member	75	2015-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/11/23	Robert Richard Ruffolo	Issuer sale	Director	5,120	0.2046%
8/11/23	Matthew Kowalsky	Issuer sale	Chief Administrative Officer	14,615	0.5842%
8/11/23	Douglas Cole	Issuer sale	Founder	1,366	0.0546%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SIGILON THERAPEUTICS, INC.	-2.56%	+4.27%	-	-	56.5M
WUXI APPTEC CO., LTD.	-3.10%	-4.19%	+32.67%	+59.47%	65.28B
ARGENX SE	+0.33%	+0.33%	+10.16%	+78.07%	54.57B
LONZA GROUP AG	+0.16%	+1.73%	+9.89%	+102.10%	53.59B
IQVIA HOLDINGS INC.	-0.75%	+1.38%	+24.89%	+50.91%	45.03B
BEONE MEDICINES AG	-1.30%	-4.80%	+16.05%	+114.76%	42.17B
REVOLUTION MEDICINES, INC.	+1.26%	-5.26%	+221.12%	+900.64%	39.42B
CELLTRION, INC.	-0.74%	-4.46%	+11.00%	+44.65%	32.71B
GENMAB A/S	+1.11%	+15.18%	+60.27%	+49.33%	26.5B
WUXI BIOLOGICS (CAYMAN) INC.	+1.84%	-7.69%	+24.05%	-9.70%	24.01B
Average	-0.35%	-0.17%	+45.57%	+154.47%	42.59B
Weighted average by Cap.	-0.42%	-0.59%	+42.44%	+153.36%